## **Product** Data Sheet

## Human enteropeptidase-IN-1

**Cat. No.:** HY-147927

**CAS No.:** 1802891-20-8

Molecular Formula:  $C_{20}H_{18}N_4O_7$ Molecular Weight: 426.38

Target: Enteropeptidase

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

NH N-O

## **BIOLOGICAL ACTIVITY**

Description	Human enteropeptidase-IN-1 (compound 6b) is a highly potent, orally active and low systemic exposure enteropeptidase inhibitor. Human enteropeptidase-IN-1 boosts the increase in fecal protein output, and exhibits potent body weight loss in diet-induced obese (DIO) rat model. Human enteropeptidase-IN-1 can be used for anti-obesity research <sup>[1]</sup> .
IC <sub>50</sub> & Target	$IC_{50(initial)}$ : 20 nM (enteropeptidase) <sup>[1]</sup> $IC_{50(app)}$ : 1.2 nM (enteropeptidase) <sup>[1]</sup>
In Vitro	Human enteropeptidase-IN-1 (compound 6b) has inhibitory activity against enteropeptidase with $IC_{50(initial)}^*$ of 20 nM and $IC_{50(app)}^{**}$ of 1.2 nM $^{[1]}$ . (* $IC_{50(initial)}^*$ refers to the inhibitory activity of human enteropeptidase after 6 min of incubation with the enzyme, substrate, and compound.) (** $IC_{50(app)}^*$ refers to the apparent $IC_{50}^*$ value after 120 min of incubation with the enzyme, substrate, and compound.) MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Ikeda Z, et al. Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity. J Med Chem. 2022 Jun 23;65(12):8456-8477.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA